Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free NIVF Stock Alerts

NewGenIvf Group (NIVF) Competitors

NewGenIvf Group logo
$0.90 -0.12 (-11.82%)
As of 10:33 AM Eastern
Compare

NIVF vs. DHAC, BACK, BTTX, UPHL, and ACONW

Should you buy NewGenIvf Group stock or one of its competitors? MarketBeat compares NewGenIvf Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NewGenIvf Group include Digital Health Acquisition (DHAC), IMAC (BACK), Better Therapeutics (BTTX), UpHealth (UPHL), and Aclarion (ACONW). These companies are all part of the "healthcare" industry.

How does NewGenIvf Group compare to Digital Health Acquisition?

Digital Health Acquisition (NASDAQ:DHAC) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

1.0% of Digital Health Acquisition shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 6.6% of Digital Health Acquisition shares are owned by insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Digital Health AcquisitionN/A N/A N/A
NewGenIvf Group N/A N/A N/A

NewGenIvf Group has higher revenue and earnings than Digital Health Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Digital Health AcquisitionN/AN/AN/AN/AN/A
NewGenIvf Group$4.73M0.05$9.88MN/AN/A

Digital Health Acquisition has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, NewGenIvf Group has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

In the previous week, NewGenIvf Group had 9 more articles in the media than Digital Health Acquisition. MarketBeat recorded 9 mentions for NewGenIvf Group and 0 mentions for Digital Health Acquisition. Digital Health Acquisition's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.11 indicating that Digital Health Acquisition is being referred to more favorably in the media.

Company Overall Sentiment
Digital Health Acquisition Neutral
NewGenIvf Group Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Digital Health Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

NewGenIvf Group beats Digital Health Acquisition on 5 of the 7 factors compared between the two stocks.

How does NewGenIvf Group compare to IMAC?

IMAC (NASDAQ:BACK) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, NewGenIvf Group had 9 more articles in the media than IMAC. MarketBeat recorded 9 mentions for NewGenIvf Group and 0 mentions for IMAC. IMAC's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.11 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Neutral
NewGenIvf Group Neutral

5.8% of IMAC shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IMAC has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, NewGenIvf Group has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

NewGenIvf Group has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K2.16-$9.42M-$3.12N/A
NewGenIvf Group$4.73M0.05$9.88MN/AN/A

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
NewGenIvf Group N/A N/A N/A

Summary

NewGenIvf Group beats IMAC on 7 of the 10 factors compared between the two stocks.

How does NewGenIvf Group compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, NewGenIvf Group had 9 more articles in the media than Better Therapeutics. MarketBeat recorded 9 mentions for NewGenIvf Group and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.11 indicating that Better Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Better Therapeutics Neutral
NewGenIvf Group Neutral

NewGenIvf Group has higher revenue and earnings than Better Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A
NewGenIvf Group$4.73M0.05$9.88MN/AN/A

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
NewGenIvf Group N/A N/A N/A

Better Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, NewGenIvf Group has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

Given Better Therapeutics' higher probable upside, research analysts plainly believe Better Therapeutics is more favorable than NewGenIvf Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Better Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

NewGenIvf Group beats Better Therapeutics on 5 of the 9 factors compared between the two stocks.

How does NewGenIvf Group compare to UpHealth?

NewGenIvf Group (NASDAQ:NIVF) and UpHealth (NYSE:UPHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
UpHealth
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Company Net Margins Return on Equity Return on Assets
NewGenIvf GroupN/A N/A N/A
UpHealth N/A N/A N/A

66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 56.1% of UpHealth shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by company insiders. Comparatively, 34.2% of UpHealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NewGenIvf Group has higher earnings, but lower revenue than UpHealth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewGenIvf Group$4.73M0.05$9.88MN/AN/A
UpHealth$130M0.00-$56.42M$1.470.00

In the previous week, NewGenIvf Group had 9 more articles in the media than UpHealth. MarketBeat recorded 9 mentions for NewGenIvf Group and 0 mentions for UpHealth. UpHealth's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.11 indicating that UpHealth is being referred to more favorably in the news media.

Company Overall Sentiment
NewGenIvf Group Neutral
UpHealth Neutral

NewGenIvf Group has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market. Comparatively, UpHealth has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Summary

NewGenIvf Group beats UpHealth on 5 of the 9 factors compared between the two stocks.

How does NewGenIvf Group compare to Aclarion?

NewGenIvf Group (NASDAQ:NIVF) and Aclarion (NASDAQ:ACONW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Company Net Margins Return on Equity Return on Assets
NewGenIvf GroupN/A N/A N/A
Aclarion N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aclarion
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, NewGenIvf Group had 9 more articles in the media than Aclarion. MarketBeat recorded 9 mentions for NewGenIvf Group and 0 mentions for Aclarion. Aclarion's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.11 indicating that Aclarion is being referred to more favorably in the news media.

Company Overall Sentiment
NewGenIvf Group Neutral
Aclarion Neutral

66.2% of NewGenIvf Group shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NewGenIvf Group has higher revenue and earnings than Aclarion.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewGenIvf Group$4.73M0.05$9.88MN/AN/A
Aclarion$77.88KN/AN/AN/AN/A

Summary

NewGenIvf Group beats Aclarion on 5 of the 6 factors compared between the two stocks.

Get NewGenIvf Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for NIVF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIVF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NIVF vs. The Competition

Export
MetricNewGenIvf GroupMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$225K$8.31B$6.40B$12.44B
Dividend YieldN/A2.98%2.76%5.28%
P/E RatioN/A21.2520.9925.77
Price / Sales0.0519.39556.7187.38
Price / Cash0.0286.2043.4956.67
Price / Book0.015.8610.387.20
Net Income$9.88M$183.47M$3.57B$335.78M
7 Day Performance4.45%8.70%4.13%4.04%
1 Month Performance-54.11%6.56%1.67%2.70%
1 Year Performance-99.89%4.89%34.50%36.92%

NewGenIvf Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NIVF
NewGenIvf Group
1.6849 of 5 stars		$0.90
-11.8%		N/A-99.9%$225K$4.73MN/AN/A
DHAC
Digital Health Acquisition
N/A$0.15
-3.3%		N/A-85.3%$548KN/AN/A2,021
BACK
IMAC
N/A$0.05
flat		N/A+39.4%$174K$72.05KN/A180
BTTX
Better Therapeutics
N/AN/AN/AN/A$4KN/AN/A40
UPHL
UpHealth
N/A$0.00
flat		N/A-66.7%$2K$130MN/A1,750

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NIVF) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
I was right about SpaceX. Now here's the part that matters
Goldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...
The Oxford Club | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
One algorithm, 17 years, nearly 2,000% total returns
A physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,0...
Porter & Company | Sponsoredtc pixel